Low-Dose Amitriptyline vs. CBT-I for Comorbid Insomnia: Statistical Non-Inferiority Meets Clinical Reality
Highlights
- Low-dose amitriptyline (10-20 mg) met the criteria for non-inferiority compared to group CBT-I in reducing insomnia severity among patients with medical comorbidities.
- Despite statistical non-inferiority, CBT-I achieved a significantly higher clinical response rate (58%) compared to amitriptyline (41%).
- Amitriptyline was associated with a higher burden of anticholinergic side effects and a high rate of sleep deterioration (68%) following treatment discontinuation.
- CBT-I remains the recommended first-line therapy due to its superior safety profile and more durable clinical benefits.
The Challenge of Insomnia in Medical Comorbidity
MedXY registered readers
Sign in free to continue reading
Create or use your MedXY account to unlock the complete article.
This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.